On Tuesday, the first day of Cannabis Europa London 2026 opened at the hotel congress center on the Thames riverbank. The conference has been Europe’s most important industry gathering for years, and this May-Whitsun weekend it has taken on unusual weight. Those following the live report from Business of Cannabis read a clear assessment. Germany’s cannabis market is becoming a strategic stage where wholesale consolidators, tech platforms, and major banks are reshuffling themselves in an M&A wave.
📑 Inhaltsverzeichnis
Four Archetypes, One Consolidation Wave
Niklas Kouparanis, CEO of Bloomwell, defined four archetypes consolidating the German market during the panel All Eyes on Germany. First, German-on-German acquisitions, where established German players swallow smaller competitors. Second, Canadian operators pushing into Europe after their home market matured. Third, a second wave of US multistate operators following Schedule III rescheduling. Fourth, Big Pharma, tobacco, and food-and-beverage conglomerates now viewing cannabis not as a risk field but as a mature vertical.
David Henn, board member of Cannamedical, formulated the assessment even more pointedly. „The biggest deals in Germany are still to come,“ the report quoted him. Henn advocated building substance rather than betting on multiple speculation. This view aligns with the observation from a third panelist, Benedikt Sons of Cansativa. Sons reported that wholesale multiples in the German cannabis world have compressed to roughly six times EBITDA, while tech and patient platforms continued to achieve factors between ten and fifteen.
Banks Enter, Standards Rise
The structural break was marked by Franziska Katterbach, partner at law firm Oppenhoff. She diagnosed a renaissance of the industry with major M&A deals and bank financing. Concretely, she pointed to Deutsche Bank, which according to her account has imposed a minimum revenue threshold of twenty million euros for credit relationships with cannabis companies. Those below it cannot refinance through classical channels; those above it move into the respectable mid-market corridor. This threshold is not high enough to strangle the market, but high enough to accelerate consolidation logic.
Those familiar with background figures from recent weeks see the connection. German import figures declined slightly in the first quarter of 2026 for the first time in two years. A detailed analysis of the 50.5 tons in Q1 2026 shows that demand is not collapsing but rather supplier and importer structures are being reorganized. This is exactly what fueled the London debate on Day 1. To survive, you need scale. Scale comes only through consolidation. Consolidation costs capital. Capital today comes more readily from banks than from venture investors.
Tech Platforms Become the Real Asset Class
Yuval Soiref, board member of Green Success, brought the tech argument to the second major panel. He spoke about AI-supported infrastructure for patient management and supply platforms as a remedy against market fragmentation. The spin-off described simultaneously by Business of Cannabis under the keyword BH Labs is the logical consequence of this view. For those wanting to compare the European market structurally, the British market with 30 tons of annual import volume offers an instructive contrast to Germany. Cannabis companies are increasingly positioning themselves as technology firms with pharmaceutical supply chains rather than as pharma firms with an IT layer.
Aras Azadian, board member of Avicanna, pinpointed the other driver. „I’ve experienced a complete change in tone over the last three months,“ the report quoted him. Fortune 100 and Fortune 500 companies suddenly showed interest in the European cannabis market. The trigger is clear. The US rescheduling to Schedule III has shifted the cannabis question from a compliance threat to a regulatory clarification. Those who couldn’t do so before are now strategically reconsidering.
The Unresolved Question: Who Owns the Reform?
The actually most interesting panel on Day 1 was not the German one but the international law panel. Kojo Koram from the Transnational Research Centre warned against purely corporate-driven reform. Countries like Ghana would be developed primarily as export bases for Europe and North America without local patient care or traditional cultivation structures benefiting. Steve Rolles from the Transform Drug Policy Foundation complemented this thought with a sentence that should be a thorn in the side of the German debate about telemedicine, cultivation associations, and pharmacy markets: „Drug reform has historically always been a bottom-up process, carried by local activists, patient groups, and traditional cultivators.“
Carola Perez from the Spanish patient organization „We, The Patients“ provided the most sobering assessment. Patient voices are only consultative, not decisive, in European reform processes. This is exactly the breach becoming visible in Berlin. As the market aligns toward institutional capital, big pharma, and tech platforms, the reform coalition changes. The voices that politically achieved the Cannabis Act sit in the second row of the conference, not on the main stages.
What Day 1 Means for Germany
Three conclusions press themselves forward. First, the medicinal cannabis market will be shaped more by capital concentration than political reform over the next twelve months. Those who in 2026 still claim independence as a German mid-market player should have a plan for one of the four acquisition waves outlined by Kouparanis. Second, the gap between six times EBITDA for wholesale multiples and ten to fifteen times for tech multiples is a signal to the industry that operational margin strength has become more important than revenue growth. Third, the MedCanG reform standstill in Berlin is no longer a risk for investors but a calculable condition.
The second day of Cannabis Europa London 2026 runs today, with the post-report and voices interviews providing further details. It will be interesting to see whether the telemedicine crossroads session with Kristine Lütke and Dirk Heitepriem more precisely defines the German pharmacy procurement model that has dominated the overall European market to date. Those who kept the preview of Cannabis Europa 2026 in mind see in Day 1 confirmation of the question raised there. Europe’s cannabis market is currently crossing the billion-euro threshold, and the question is no longer whether but who will capture the consolidation returns.
Frequently Asked Questions
What is Cannabis Europa London 2026?
Cannabis Europa is a long-established European industry conference with its annual main event in London. On May 26-27, 2026, representatives from politics, industry, and science meet to strategically organize the European cannabis market. Alongside the Berlin Medicinal Cannabis Congress, it is the most important B2B platform for the DACH industry.
Which German companies were prominently represented on Day 1?
On the panel All Eyes on Germany sat the board members Niklas Kouparanis from Bloomwell, David Henn from Cannamedical, and Benedikt Sons from Cansativa, complemented by business lawyer Franziska Katterbach from Oppenhoff. Moderation came from Tristan Gervais of T Capital. The round was exemplary for the German consolidation debate between wholesale actors, tech platforms, and legal consultancy.
Which specific market figures were mentioned?
Prohibition Partners projected the European medicinal market at over 1.5 billion euros. From Germany, wholesale multiples of around six and tech platform multiples of ten to fifteen were reported. Deutsche Bank has set a minimum revenue threshold of twenty million euros for cannabis credit. In the United Kingdom, the stark contrast was noted that the private prescription market faces only eight NHS prescriptions against eight million patients on NHS waiting lists for pain and mental health treatment.
What role did US rescheduling play at the conference?
Rescheduling to Schedule III was repeatedly characterized as „the most significant shift in US drug policy in half a century.“ The strategic consequence is a convergence of US and EU regulatory frameworks. Aras Azadian from Avicanna reported a fundamental shift in tone from Fortune companies toward the European cannabis market since February 2026.
What comes today on Day 2?
Day 2 brings, among other things, the telemedicine crossroads session with German policy consultant Kristine Lütke and Dirk Heitepriem from the BvCW, supplemented by deal-flow and M&A panels with investment houses T Capital and AMA Invest. The full post-report including voices interviews will be available in the coming days.
Wie siehst du die Konsolidierung des deutschen Cannabismarkts?
Sources: Business of Cannabis live report „Cannabis Europa London 2026 Key Insights Day 1“ from May 26, 2026; Cannabis Europa speaker directory 2026; own research on German import figures Q1 2026 and consolidation multiples based on Krautinvest and Prohibition Partners.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
